Achyut Healthcare Limited is an Ahmedabad-based pharmaceutical entity that has undergone a significant strategic transformation from a financial services firm to an integrated healthcare provider. Since its listing on the **BSE SME platform** in **March 2022**, the company has aggressively expanded its capital base, transitioned to the **BSE Main Board**, and is currently pivoting from a trading-centric model to a high-value manufacturing enterprise. --- ### **Strategic Pivot: From Trading to Integrated Manufacturing** Achyut Healthcare is executing a vertical integration strategy to reduce reliance on third-party sourcing and capture higher margins through in-house production. * **Current Model:** Primarily focused on the distribution and sale of pharmaceutical formulations (**Tablets, Capsules, Oral Liquids, and Injectables**) and the trading of **Active Pharmaceutical Ingredients (API)**, raw materials, and packing materials. * **Manufacturing Transition:** The company is establishing a new manufacturing facility at **Bhat Village, Ahmedabad**. This plant is designed to produce: * **General Tablets** * **Hard and Soft Gelatin Capsules** * **Anesthetic Liquids** * **Sachets** * **Timeline:** Commercial production at the new facility is projected to commence in **January 2026**. * **Market Expansion:** While currently domestic-focused, the company has set a strategic target to initiate **export operations** in the near future to diversify its revenue streams. --- ### **Financial Performance & Growth Trajectory** The company has demonstrated robust financial scaling, characterized by triple-digit growth in key metrics during the most recent audited fiscal year. | Metric (₹ in Lakhs) | FY 2023-24 | FY 2022-23 | Growth (%) | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **686.33** | **328.73** | **108.7%** | | **Net Profit (PAT)** | **57.32** | **23.12** | **147.9%** | | **Transfer to General Reserve** | **57.32** | - | - | * **Profit Retention:** The Board has opted **not to recommend a dividend**, prioritizing the retention of profits to fund ongoing **CAPEX** and manufacturing infrastructure. * **Institutional Interest:** Foreign Portfolio Investors (**FPI**) currently hold a **6.11%** stake in the company (**1,028,250 shares**). --- ### **Aggressive Capital Restructuring & Market Migration** To fund its transition and improve stock liquidity, Achyut Healthcare has utilized frequent corporate actions, culminating in a migration to the **BSE Main Board** on **January 2, 2026**. **Evolution of Share Capital:** * **Stock Split (Nov 2024):** Sub-division of face value from **₹10/-** to **₹1/-** per share. * **Bonus Issues:** * **May 2023:** **1:2 ratio** (1 share for every 2 held). * **October/December 2024:** **4:10 ratio** (4 shares for every 10 held). * **Preferential Allotments:** * **January 2024:** **2,808,000 shares** at **₹56/-** (Pre-split) to fund plant and machinery. * **March 2026:** **5,800,000 shares** at **₹6/-** (Post-split) to Promoters and Non-Promoters. **Current Capital Position (Post-March 2026):** The total **Issued, Subscribed, and Paid-up Capital** stands at **₹24,13,57,000**, divided into **24,13,57,000 equity shares** with a face value of **₹1/-**. --- ### **Operational Infrastructure & Logistics** The company maintains a centralized hub in Gujarat to manage its administrative and industrial requirements. | Facility Type | Location | | :--- | :--- | | **Corporate Office** | 504 Iscon Elegance, Prahlad Nagar Cross Road, Ahmedabad | | **Registered Office** | 610, Colonade, Iscon-Ambli Road, Ahmedabad | | **Manufacturing Plant** | Survey No. 1078, Bhat Village, Ahmedabad | | **Storage/Godown** | 56, Changodar Industrial Estate, Sanand, Ahmedabad | --- ### **Risk Management & Regulatory Landscape** Achyut Healthcare operates within a highly regulated environment and has established a framework to mitigate operational and market risks. * **Price Control Impact:** A significant portion of the portfolio falls under the **Drug Price Control Order (DPCO)**. Changes in government pricing notifications represent a direct risk to profit margins. * **Competitive Intensity:** The company faces **very high competition** from large-scale pharmaceutical multinationals and agile new entrants. * **Related Party Exposure:** The company maintains a significant trading relationship with **Zenith Healthcare Limited** for API and raw materials, with an approved transaction limit of up to **₹100 Crores**. * **Mitigation Strategies:** * **Commodity Risk:** Managed through **forward booking** and proactive vendor development. * **Human Resources:** Implementation of a **Strategic Talent Management System** to combat industry-wide attrition. * **Compliance:** Regular **Reconciliation of Share Capital Audits** and internal audits by **M/s. Mohta Khetawat & Co.** ensure governance standards are met. --- ### **Investment Thesis Summary** Achyut Healthcare is currently in a **high-growth, high-investment phase**. The transition from a trading entity to a manufacturer (expected **January 2026**) is the primary value driver. While the company faces risks from **DPCO price caps** and intense competition, its successful migration to the **BSE Main Board** and aggressive capital expansion signal a commitment to institutional-grade transparency and long-term industrial scaling.